IP Library Granted Patent US 9,839,695
Granted Patent B2
US 9,839,695 · App. 15/136,632 · Granted Dec 12, 2017

Polymer-active agent conjugate

Inventor: Antoni Kozlowski (Huntsville, AL)
Assignee: Nektar Therapeutics
A61K47/48215A61K31/7088A61K47/48776A61K47/60A61K47/6901C08G63/91C08G65/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,695
App. No.
15/136,632
Granted
Dec 12, 2017
Kind
B2
Abstract

The invention provides for preparing a polymer-active agent conjugate, the method comprising the steps of reacting an amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.

Claims (12)

1. A polymer-active agent conjugate, the polymer-active agent conjugate prepared by a method comprising:

reacting a polymeric amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate,

wherein the polymeric amino acid derivative was prepared by a method comprising:

providing a linear poly(ethylene glycol) having one terminal hydroxyl group and having a molecular weight of about 20,000 daltons;

reacting the terminal hydroxyl group of the poly(ethylene glycol) with di(1-benzotriazolyl) carbonate to form a 1-benzotriazolylcarbonate ester of the poly(ethylene glycol);

reacting the 1-benzotriazolylcarbonate ester of the poly(ethylene glycol) with lysine to form in one or more steps a polymeric amino acid derivative, said polymeric amino acid derivative having the following structure:

wherein:

PEG is a linear poly(ethylene glycol) having a molecular weight of about 20,000 daltons,

Z is N-succinimidyl, and

the biologically active agent is an oligonucleotide.

2. The polymer-active agent conjugate of claim 1 , wherein each PEG is capped with a capping group.

3. The polymer-active agent conjugate of claim 2 , wherein the capping group is methoxy.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
SECURITY INTEREST Recorded Jul 8, 2016
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 039111/0745 →
Continuity (13)
Continuation 14467634 · Aug 25, 2014
Continuation 14059020 · Oct 21, 2013
Continuation 13664021 · Oct 30, 2012
Continuation 13154917 · Jun 7, 2011
Continuation 12756905 · Apr 8, 2010
Continuation 12433874 · Apr 30, 2009
Continuation 12150136 · Apr 25, 2008
Continuation 11492133 · Jul 24, 2006
Continuation 10727337 · Dec 2, 2003
Continuation 10068371 · Feb 6, 2002
Division 09740556 · Dec 18, 2000
Provisional Application 60171834 · Dec 22, 1999
Related Publication 20160310606A1 · Oct 27, 2016